EUVIMEDEUVIMED entdecken
Crossref

Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation

Pavithra Ramakrishnan iD, James Campbell, Daphne Moutsoglou, Megan Ghai, Eugenia Shmidt, Byron P Vaughn

Inflammatory Bowel Diseases · 01.07.2026 · 32 (7) · 1313-1320

DOI: 10.1093/ibd/izag038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 23.03.2026. Verfasst von Pavithra Ramakrishnan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Minnesota, Minneapolis, MN 55455, United States. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with inflammatory bowel disease (IBD), Clostridioides difficile infection (CDI) presents with clinical features indistinguishable from the underlying disease. Sequential polymerase chain reaction (PCR) and enzyme immunoassay (EIA) testing reduce overdiagnosis; however, discordant results create management uncertainties.

Methods

We conducted a retrospective cohort study of IBD patients with positive C. difficile PCR testing at 2 institutions between April 2022 and December 2023. Patients were stratified by EIA toxin (TOX) results. Demographic, clinical, laboratory, and therapeutic data were extracted, and outcomes assessed included CDI-directed therapy or escalation of IBD treatment.

Results

Of 575 IBD patients tested, 117 met inclusion criteria. Among them, 79% (93/117) were PCR+/TOX− and 21% (24/117) were PCR+/TOX+. PCR+/TOX+ patients had significantly higher CRP (98 vs 6 mg/L, P = .005). PCR+/TOX− patients had more severe underlying IBD and higher rates of steroid use (48% vs 21%, P = .02) and were less likely to receive CDI treatment (72% vs 96%, P = .01) but were significantly more likely to require IBD therapy escalation (54% vs 25%, P = .004). Multivariable analysis showed PCR+/TOX− status (odds ratio [OR], 3.2; P = .045) and moderate-to-severe endoscopic disease within 1 year of testing (OR, 5.6; P = .0007) were significant predictors of IBD treatment escalation.

Conclusions

Elevated CRP may help distinguish true CDI in IBD. PCR+/TOX+ patients typically respond to CDI-directed therapy, whereas PCR+/TOX− patients more often require escalation of IBD treatment, suggesting noninfectious inflammation as the primary driver of symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesClostridioides difficileClostridium InfectionsHumansRetrospective StudiesPolymerase Chain ReactionFemaleMaleImmunoenzyme Techniques

Stichwörter der Autor:innen

Clostridioides difficileinflammatory bowel diseasesreflex testing discordant

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Minnesota, Minneapolis, MN 55455, United States.
  • Research department , MNGI Digestive Health, Minneapolis, MN 55413, United States.
  • Gastroenterology Section, Veterans Affairs Medical Center, Minneapolis, MN 55417, United States.
  • Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN 55455, United States.

ORCID-Profile: Pavithra Ramakrishnan

Zitieren

APA

Ramakrishnan, P., Campbell, J., Moutsoglou, D., Ghai, M., Shmidt, E., & Vaughn, B. P. (2026). Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation. Inflammatory Bowel Diseases, 32(7), 1313-1320. https://doi.org/10.1093/ibd/izag038

Vancouver

Ramakrishnan P, Campbell J, Moutsoglou D, Ghai M, Shmidt E, Vaughn BP. Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation. Inflammatory Bowel Diseases. 2026;32(7):1313-1320. doi:10.1093/ibd/izag038

BibTeX
@article{Ramakrishnan2026,
  author = {Ramakrishnan, Pavithra and Campbell, James and Moutsoglou, Daphne and Ghai, Megan and Shmidt, Eugenia and Vaughn, Byron P},
  title = {Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {7},
  pages = {1313--1320},
  doi = {10.1093/ibd/izag038}
}
Kostenlos starten →